Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Sales and Divestitures: 2015-2021

Historic Gains from Sales and Divestitures for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Sep 2021 value amounting to $899,025.

  • Arrowhead Pharmaceuticals' Gains from Sales and Divestitures rose 13.05% to $931,063 in Q1 2022 from the same period last year, while for Mar 2022 it was $931,063, marking a year-over-year increase of 13.05%. This contributed to the annual value of $899,025 for FY2021, which is 22.42% down from last year.
  • According to the latest figures from FY2021, Arrowhead Pharmaceuticals' Gains from Sales and Divestitures is $899,025, which was down 22.42% from $1.2 million recorded in FY2020.
  • Arrowhead Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $2.2 million during FY2019, with a 5-year trough of $786,667 in FY2017.
  • Its 3-year average for Gains from Sales and Divestitures is $1.4 million, with a median of $1.2 million in 2020.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 89.09% in 2017, then crashed by 47.26% in 2020.
  • Arrowhead Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $786,667 in 2017, then spiked by 69.70% to $1.3 million in 2018, then surged by 64.59% to $2.2 million in 2019, then plummeted by 47.26% to $1.2 million in 2020, then declined by 22.42% to $899,025 in 2021.